Clinical Trial Update: ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 study evaluating ST-067 in combination with CD19-directed CAR T-cell therapy (Liso-cel) for relapsed/refractory diffuse large B-cell lymphoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Liso-cel (lisocabtagene maraleucel)
• ST-067

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1, Phase 2 | Status: RECRUITING